tbuckley/cabot-search huggingface dataset:
Maternal Syndrome in Hydrops Foetalis
Authors: J. S. Scott
Journal: BMJ (1964)

ICARK"a Court of Law and might even involve the psychiatrist who repeats them in a libel action.Freud himself had later to admit that the accusations his female patients made against their fathers which he at first believed were the product of their imagination and dis- torted memory.Every policeman knows how readily people under some emotional strain may accuse themselves of murder or serious crimes they have never committed.However, such subterfuges and treating the legal profession with their own medicine should not be necessary, nor need we wait, as Dr. Spencer suggests, till some psychiatrist is prepared to go to prison.I am sure, Sir, that the whole profession and the common man in the street would wholeheartedly stand behind the B.M.A. or any medical M.P. who would propose to bring the law for the physi- cian (and incidentally the priest) in line with the solicitor, whose communications with his client are legally recognized as privileged.-I am, etc., Leicester.
Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Authors: Sudarsan Kollimuttathuliam, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, Noa Biran, David H. Vesole, Themba Nyirenda, Andrew L. Pecora, Stuart L. Goldberg, Andre Goy, Michele L. Donato
Journal: Blood (2019)
FDG PET/CT and MRI in Primary Spinal Cord Glioblastoma
Authors: Guohua Shen, Huan Ma, Lili Pan, Minggang Su, Anren Kuang
Journal: Clinical Nuclear Medicine (2019)

Abstract Glioblastoma is the most common primary malignant tumor of the central nervous system, most of which occur in the brain. Primary spinal cord glioblastoma is extremely rare. A 47-year-old woman presented with recurrent and progressive paresthesia and paralysis of right lower extremity. MR examination revealed a marked nodular enlargement of spinal cord at the T12 level, showing heterogeneous enhancement. FDG PET/CT showed this intraspinal lesion with high FDG uptake. Imaging findings indicated a possible diagnosis of malignant neoplasm. Surgical resection was performed, and the pathologic results confirmed a primary spinal cord glioblastoma.
High-Throughput BCR Sequencing and Single-Cell Transcriptomics Reveal Distinct Transcriptional Profiles Associated with Subclonal Evolution of Follicular Lymphoma
Authors: Cornelis A.M. van Bergen, Marvyn T. Koning, Edwin Quinten, Agnieszka Mykowiecka, Julieta Sepulveda, Ramin Monajemi, Ruben A.L. De Groen, Joost Vermaat, Susan L. Kloet, Szymon M. Kielbasa, Marcelo A. Navarrete, Pawel Górecki, Hendrik Veelken
Journal: Blood (2019)
NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE
Authors: Ina Ly, Raquel Thalheimer, Wenli Cai, Miriam Bredella, Vanessa Merker, Scott Plotkin, Justin Jordan
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Neurofibromas affect 40–50% of neurofibromatosis type 1 (NF1) patients and can cause significant morbidity and mortality. They grow more rapidly during childhood and adolescence but studies in adults are limited by their retrospective nature and follow-up time &lt; 3 years. The long-term natural history of neurofibromas remains unknown. No guidelines exist on the need and frequency of surveillance imaging for patients. Whole-body MRI (WBMRI) can detect whole-body tumor burden, including internal neurofibromas. METHODS 17 adult NF1 patients who underwent WBMRI between 2007–2010 (Scan 1) underwent repeat WBMRI between 2018–2019 (Scan 2). Internal neurofibromas were segmented on short tau inversion recovery (STIR) sequences and tumor volume was calculated using a computerized volumetry and three-dimensional segmentation software. Circumscribed tumors were defined as discrete; invasive tumors or those involving multiple nerves were defined as plexiform. Tumor growth and shrinkage were defined as volume change ≥ 20% over the entire study period. RESULTS Median patient age was 43 years during Scan 1 and 53 years during Scan 2. Median time between Scan 1 and 2 was 9 years. A total of 140 neurofibromas were assessed. 24% of tumors grew by a median 63% (6.8% per year). 54% of tumors spontaneously decreased in volume by a median 60% (7% per year) without treatment. On a per-patient basis, 18% of patients had overall tumor growth and 41% overall tumor shrinkage. 8 new tumors developed in 7 patients. 16 tumors resolved entirely without medical or surgical intervention. Growth behavior did not correlate with discrete or plexiform morphology. CONCLUSION A subset of internal neurofibromas in adult NF1 patients grow significantly over a long-term period, suggesting that continued monitoring of these patients may be warranted. Surprisingly, more than half of neurofibromas shrink spontaneously without intervention. Continued patient enrollment and correlation of imaging findings with functional outcomes are underway.
Genotyping and De Novo Discovery of Allelic Variants at the Brassicaceae Self-Incompatibility Locus from Short-Read Sequencing Data
Authors: Mathieu Genete, Vincent Castric, Xavier Vekemans
Journal: Molecular Biology and Evolution (2019)

Plant self-incompatibility (SI) is a genetic system that prevents selfing and enforces outcrossing. Because of strong balancing selection, the genes encoding SI are predicted to maintain extraordinarily high levels of polymorphism, both in terms of the number of functionally distinct S-alleles that segregate in SI species and in terms of their nucleotide sequence divergence. However, because of these two combined features, documenting polymorphism of these genes also presents important methodological challenges that have so far largely prevented the comprehensive analysis of complete allelic series in natural populations, and also precluded the obtention of complete genic sequences for many S-alleles. Here, we develop a powerful methodological approach based on a computationally optimized comparison of short Illumina sequencing reads from genomic DNA to a database of known nucleotide sequences of the extracellular domain of SRK (eSRK). By examining mapping patterns along the reference sequences, we obtain highly reliable predictions of S-genotypes from individuals collected from natural populations of Arabidopsis halleri. Furthermore, using a de novo assembly approach of the filtered short reads, we obtain full-length sequences of eSRK even when the initial sequence in the database was only partial, and we discover putative new SRK alleles that were not initially present in the database. When including those new alleles in the reference database, we were able to resolve the complete diploid SI genotypes of all individuals. Beyond the specific case of Brassicaceae S-alleles, our approach can be readily applied to other polymorphic loci, given reference allelic sequences are available.
Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the Transcription Factor CREB
Authors: Maria E Balasis, Alexis Vedder, Lei Sun, Ariel Quintana, Abhishek Dhawan, Hannah Newman, Jane Merlevede, Kathy McGraw, Traci Kruer, Nana Ben-Crentsil, Jeffrey S Painter, Nathalie Droin, Thomas Cluzeau, Christopher Letson, Sheng Wei, Rami S. Komrokji, Hailing Zhang, A. Robert MacLeod, Alan F. List, Eric Solary, Pearlie K. Epling-Burnette, Eric Padron
Journal: Blood (2019)
GENE-27. MENINGIOMA RECURRENCE: ROLE OF M1/M2 TUMOUR-ASSOCIATED MACROPHAGE INFILTRATION
Authors: Dustin Proctor, Jordan Huang, Sanju Lama, Abdulrahman Albakr, Guido Van Marle, Garnette Sutherland
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Meningioma, a most common brain tumour, has a high rate of recurrence. Tumour-associated macrophages (TAMs) are the most abundant immune cell type in meningioma. TAMs display functional phenotypic diversity and may establish either an inflammatory and anti-tumoural or an immunosuppressive and pro-tumoural microenvironment. TAM subtypes present in meningioma and potential contribution to growth and recurrence is unknown. METHODS Fluorescence immunohistochemistry was used to evaluate the distribution and quantify M1 and M2 TAM populations in 30 meningioma tissues. Association between quantified M1 and M2 cells and M1/M2 ratio to tumour characteristics including WHO grade, tumour recurrence, size, location, peri-tumoural edema and patient demographics such as age and sex was examined. RESULTS TAM cells accounted for ~17% of all cells in tumour tissues. Importantly, greater than 80% of infiltrating TAMs were discovered to be of a polarized pro-tumoural M2 phenotype which positively associated with tumour size. TAM subtype profiles differed significantly between non-recurrent (n=18) and recurrent meningioma (n=12) (P=0.044). Specifically, the M1/M2 cell ratio was decreased by ~250% in recurrent tumours. CONCLUSION This study is the first to confirm existence of pro-tumoural M2 TAMs in the meningioma microenvironment and a potential role in tumour growth and recurrence.
Diagnosis of Hysteria
Authors: H. Merskey
Journal: BMJ (1965)

MBicfJORLAmong 18 explorations there were four in which incision of the periosteum revealed no pus, but drilling of the underlying bone released pus under tension Moreover, in two other cases incision of the periosteum over the point of maximum tenderness proved negative, but on further separation of the periosteum a gush of pus was released from the opposite side of the bone.In both these examples, representing one-third of the cases, aspiration wopld have been negative and failed to relieve tension, which must, however marginally, have prejudiced the vascularity of the cortex.I feel, therefore, that, although aspiration is clearly often adequate, it is not always the optimal treatment and, when negative, must be followed by exploration to exclude the possibility of inaccessible pus.In all the 17 cases quoted satisfactory healing of the bones followed without sequestrum formation.The only significant com- plication was the development in one.case of delayed avascular necrosis of the femoral head twelve months after an osteitis of the femoral neck.
GENE-09. LONG NONCODING RNA lncHLX2-7 A PUTATIVE MOLECULAR MARKER AND A THERAPEUTIC TARGET FOR GROUP III MEDULLOBLASTOMA
Authors: Keisuke Katsushima, Piyush Joshi, Bongyong Lee, Stacie Stapleton, George Jallo, Eric Raabe, Charles Eberhart, Ranjan Perera
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma (MB), a central nervous system tumor that predominantly affects children, requires aggressive therapy. It can recur as resistant disease and is recurrent medulloblastoma is frequently fatal. There are four groups of MBs (WNT, SHH, Group III, and Group Ⅳ) and they are characterized by specific mutations, copy number alterations, transcriptomic profiles, and clinical outcomes. Recent advances in noncoding RNA genome could contribute to sub-classification of medulloblastoma. The focus of this study is to identify novel long noncoding RNAs (lncRNAs) as molecular markers and potential therapeutic targets within each subgroup of MBs, in particular within the Group III. We analyzed publicly available 723 microarrays and 123 RNA-seq datasets using machine-learning statistical algorithms (random-forest and Lasso) to identify a group of putative lncRNA signatures that may be able to differentiate medulloblastoma subgroups accurately. Among those, lncHLX2-7 was highly upregulated in Group III MBs compared to other groups. RNA-FISH analysis revealed that lncHLX2-7 is highly expressed primarily in Group III MB as compared to other groups and normal brain (cerebellum). Furthermore, depletion of lncHLX2-7 significantly reduced 20- 30% of cell growth together with the induction of apoptosis in MED211 and D425-MED Group III MB cell lines (n=3, p&lt; 0.01, t-test). We present here supporting evidence that lncHLX2-7 is a novel molecular marker and potential therapeutic target for Group III MBs in children.
Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome
Authors: Gülen Hatemi, Alfred Mahr, Yoshiaki Ishigatsubo, Yeong-Wook Song, Mitsuhiro Takeno, Doyoung Kim, Melike Melikoğlu, Sue Cheng, Shannon McCue, Maria Paris, Mindy Chen, Yusuf Yazici
Journal: New England Journal of Medicine (2019)

The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet's syndrome. In a phase 2 trial involving patients with Behçet's syndrome, apremilast reduced the incidence and severity of oral ulcers. Data on the efficacy and safety of apremilast in patients with Behçet's syndrome who had active oral ulcers and had not previously received biologic agents are limited.
RTHP-08. FAILURE TO COMPLETE STANDARD RADIATION THERAPY IN GLIOBLASTOMA PATIENTS: PATTERNS FROM A NATIONAL DATABASE WITH IMPLICATIONS FOR SURVIVAL AND THERAPEUTIC DECISION MAKING
Authors: Mehran Yusuf, Jeremy Gaskins, Mark Gilbert, Shiao Woo, Eric Burton
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Approximately 5%-10% of patients with newly diagnosed glioblastoma (GBM) will fail to complete standard radiotherapy (SRT). We sought to determine the impact on survival and to identify risk factors for failure to complete SRT. METHODS A cohort of 17,451 adults with GBM were identified from the National Cancer Database. The cohort was restricted to patients diagnosed between 2005 to 2012 that were started on conventionally fractionated RT of 1.8 to 2.0 Gy per fraction to a dose of &lt; 66Gy and. Patients were stratified by RT dose achieved: (a.) completed RT &gt; 58Gy, (b.) nearly completed RT &gt; 50Gy - &lt; 58Gy, and (c.) did not complete RT &lt; 50Gy. RESULTS Radiotherapy completion rates correlated with survival, 87% of patients completed RT and had a median OS of 13.5 months, 4% were near completers (median OS 5.7 months), and 9% did not complete RT (median OS 1.9 months). Risk factors for not completing SRT were: older age, biopsy alone, government insurance, high comorbidity score and lower income zip code (all OR &gt; 1 and p-values &lt; 0.05). Twenty-eight percent of patients &gt; 80 yrs did not complete SRT (OR 2.99, 95% CI 2.36–3.80, relative to 40–49 yrs) and 19% of 70-79-yrs did not complete SRT (OR 1.99, 95% CI 1.63–2.42). CONCLUSIONS Failure to complete SRT was associated with decreased survival in our cohort. Risk factors for failure to complete SRT, include older age, biopsy alone and substantial comorbidities. Other studies have shown SRT is discontinued primarily due to clinical deterioration and/or disease progression. Therefore, these patients should be considered for alternative therapeutic management such as hypofractionated radiotherapy.
Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations
Authors: Shunichiro Yasuda, Satoru Aoyama, Ryoto Yoshimoto, Watanabe Daisuke, Hiroki Akiyama, Yoshihiro Umezawa, Ayako Nogami, Kouhei Yamamoto, Takeo Fujiwara, Yoko Edahiro, Marito Araki, Norio Komatsu, Tetsuya Fukuda, Ayako Arai, Osamu Miura, Norihiko Kawamata
Journal: Blood (2019)
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
Authors: Christof Scheid, Henk Lokhorst, Igor W Blau, Bronno Van Der Holt, Uta Bertsch, Sonja Zweegman, Katja Weisel, Edo Vellenga, Marie José Kersten, Sandra Croockewit, Elias K Mai, Reinier Raymakers, Dirk Hose, Anna Jauch, Jens Hillengass, Marian Stevens-Kroef, Marc S Raab, Kai Neben, Stephan Stilgenbauer, Annemiek Broyl, Hans-Walter Lindemann, Gerard Bos, Peter Brossart, Marinus van Marwijk Kooij, Paula F Ypma, Ulrich Dührsen, Ron Schaafsma, Thomas Hielscher, Hans Salwender, Hartmut Goldschmidt, Pieter Sonneveld
Journal: Blood (2019)
Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial
Authors: Alison D Grant, Salome Charalambous, Mpho Tlali, Aaron S Karat, Susan E Dorman, Christopher J Hoffmann, Suzanne Johnson, Anna Vassall, Gavin J Churchyard, Katherine L Fielding
Journal: The Lancet HIV (2019)
Diseases of the Urinary System
Authors: Reed M. Nesbit, Jack Lapides
Journal: Annual Review of Medicine (1951)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. ...Read More
Zoledronic Acid Boosts γδ T-Cell Activity in Children Receiving αβ+ T and CD19+ CELL-Depleted Grafts from a Haplo-Identical DONOR
Authors: Giulia Barbarito, Irma Airoldi, Alessia Zorzoli, Alice Bertaina, Andrea Petretto, Elvira Inglese, Chiara Lavarello, Letizia Pomponia Brescia, Biagio De Angelis, Gino Tripodi, Pietro Merli, Lorenzo Moretta, Franco Locatelli
Journal: Blood (2016)
SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia
Authors: Anjali S. Advani, Anna Moseley, Michaela Liedtke, Margaret R O'Donnell, Ibrahim Aldoss, Martha P. Mims, Kristen Marie O'Dwyer, Megan Othus, Harry P. Erba
Journal: Blood (2019)
Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial
Authors: M. Wetzler, A. Hellmann, J. Lipton, L. Roy, D. Jones, T. Schenk, A. Hochhaus, A. Benichou, H. Kantarjian, J. Cortes
Journal: Journal of Clinical Oncology (2009)

7027 Background: Omacetaxine (OM), a first-in-class cetaxine, shows clinical activity against Ph+ CML with a mechanism of action independent to tyrosine kinase inhibition. Patients (Pts) who have failed multiple TKIs may benefit from an alternative therapy for CML. Methods: Pts include adult CML following resistance or intolerance to at least 2 TKIs. T315I+ Pts are enrolled in a separate trial. Pts receive OM induction at 1.25 mg/m 2 subcutaneous (SC) BID for 14 days every 28 days followed by maintenance at 1.25 mg/m 2 SC BID for 7 days every 28 days (maintenance after at least one induction cycle and achievement of hematologic response). Results: 60 pts (30 chronic phase [CP], 14 accelerated phase [AP], and 16 blast phase [BP] have been enrolled with 51% having failed at least 3 prior TKIs. Median age: 58 yrs; 50% male. Median disease duration: 74 months. At baseline, 38.5% of pts had Bcr-Abl mutations including 9.6% with compound mutations. The most frequently observed mutations were F317L (11.5%) and V299L (5.8%). OM is well tolerated with transient myelosuppression as the primary toxicity. Grade 3/4 non-hematologic events are rare with pyrexia occurring in 4.3% of patients. Efficacy data are available for 30 Pts: Conclusions: Omacetaxine in multi-TKI resistant or intolerant CML is well tolerated and has achieved hematologic and cytogenetic responses in these heavily pre-treated Pts. [Table: see text] [Table: see text]
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Authors: Jiajie Hou, He Zhang, Jun Liu, Zhenjun Zhao, Jianye Wang, Zhike Lu, Bian Hu, Jiankui Zhou, Zhicong Zhao, Mingxuan Feng, Haiyan Zhang, Bin Shen, Xingxu Huang, Beicheng Sun, Chuan He, Qiang Xia
Journal: Molecular Cancer (2019)

Abstract Background Dynamic N 6 -methyladenosine (m 6 A) modification was previously identified as a ubiquitous post-transcriptional regulation that affected mRNA homeostasis. However, the m 6 A-related epitranscriptomic alterations and functions remain elusive in human cancer. Here we aim to identify the profile and outcome of m 6 A-methylation in hepatocellular carcinoma (HCC). Results Using liquid chromatography-tandem mass spectrometry and m 6 A-immunoprecipitation in combination with high-throughput sequencing, we determined the m 6 A-mRNA levels in human HCC. Human HCC exhibited a characteristic gain of m 6 A modification in tandem with an increase of mRNA expression, owing to YTH domain family 2 (YTHDF2) reduction. The latter predicted poor classification and prognosis of HCC patients, and highly correlated with HCC m 6 A landscape. YTHDF2 silenced in human HCC cells or ablated in mouse hepatocytes provoked inflammation, vascular reconstruction and metastatic progression. Mechanistically, YTHDF2 processed the decay of m 6 A-containing interleukin 11 (IL11) and serpin family E member 2 (SERPINE2) mRNAs, which were responsible for the inflammation-mediated malignancy and disruption of vascular normalization. Reciprocally, YTHDF2 transcription succumbed to hypoxia-inducible factor-2α (HIF-2α). Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer. Conclusion Our results have characterized the m 6 A-mRNA landscape in human HCC and revealed YTHDF2 as a molecular ‘rheostat’ in epitranscriptome and cancer progression.
Individualized, Low Dose, Fixed Duration Lenalidomide Maintenance Is an Effective Strategy in High MRD Disease Post Chemo-Immunotherapy in CLL: Outcomes of a Randomized Controlled Trial
Authors: Nishant Jindal, Man Updesh Singh Sachdeva, Arihant Jain, Gaurav Prakash, Alka Khadwal, Sreejesh Sreedharanunni, Neelam Varma, Pankaj Malhotra, Deepesh Lad
Journal: Blood (2019)
Fast CMV and EBV Reactivations after Ruxolitinib for Graft-Versus-Host Disease Treatment
Authors: Dujardin Adèle, Pierre Morel, Alexis Caulier, Magalie Joris, Amandine Charbonnier, Berengere Gruson, Marine Quint, Marie-Noëlle Lacassagne, Sandrine Castelain, Jean-Pierre Marolleau, Delphine Lebon
Journal: Blood (2019)
The Role of Histone Demethylases and DNA Methyltransferases in the Transcription Regulation of HOX Genes in PML-RARa+ AML Patients
Authors: Katerina Rejlova, Alena Musilova, Martina Slamova, Karel Fiser, Karolina Skvarova Kramarzova, Marketa Zaliova, Jan Trka, Julia Starkova
Journal: Blood (2016)